3rd Oct 2013 05:41
THOUSAND OAKS (Alliance News) - Amgen (AMGN) and AstraZeneca (AZN.L, AZN), with its biologics research and development arm MedImmune, reported the upcoming presentation of several key studies evaluating brodalumab, a human monoclonal antibody targeting the interleukin-17 or IL-17 receptor, to treat moderate to severe psoriasis at the 22nd Congress of the European Academy of Dermatology and Venereology in Istanbul, October 2-6, 2013.
The Phase 2 data showed that the primary and secondary end points were met, including many patients achieving and maintaining total skin clearance with continued brodalumab therapy.
Both the firms announced the initiation of the Phase 3 program in moderate to severe psoriasis for brodalumab. The program includes three Phase 3 studies evaluating treatment with brodalumab compared with ustekinumab and/or placebo.
Copyright RTT News/dpa-AFX
Related Shares:
Astrazeneca